Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of hyperbaric oxygen therapy as a potential treatment for patients experiencing nerve damage, known as peripheral neuropathy, after receiving certain breast cancer medications called paclitaxel analogs. The main goal is to see if this therapy is safe and effective for improving symptoms in these patients.

To be eligible for the trial, participants need to be women aged 18 to 60 who have recently been diagnosed with breast cancer and are experiencing nerve damage rated at level 1 or higher after their treatment. However, there are some conditions that could prevent someone from participating, such as certain health issues or if they are currently being treated for other types of cancer. For those who qualify, the trial will provide more information on what to expect during the treatment process.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with newly diagnosed breast cancer by pathology
• • 2. Age 18-60 years
• • 3. ECOG 0-2
• • 4. CIPN patients with NCI-CTCAE grade 1 or higher after treatment with paclitaxel-based drugs
• Exclusion Criteria:
• • 1. Patients with contraindications to hyperbaric oxygen i. Untreated pneumothorax. ii. concomitant administration of disulfiram. iii. concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. iv. premature and/or low body mass newborns.
• • iv. Premature and/or low body mass neonates.
• • 2. Other cancers